Aclaris Therapeutics, Inc.
NASDAQ:ACRSBiotechnology
+$0.03 today
- Market cap
- $555.14M
- Beta
- 0.80
- P/E (TTM)
- -8.2
- EPS (TTM)
- -$0.54
Volume 2.94M
Average 1.40M
ACRS EBITDA Margin
EBITDA as a percentage of revenue.
Aclaris Therapeutics, Inc.NASDAQ: ACRS
EBITDA Margin · Q1 FY2026 · quarter ended Mar 2026
EBITDA Margin widens to -988.1%
EBITDA Margin was -988.1% in Q1 FY2026, up 225.4 pp from a year earlier. On a trailing-twelve-month basis it was -843.9%, down 542.0 pp year over year. Over 3 fiscal years it narrowed by 540.2 pp.
Context
- EBITDA Margin widened in 1 of the last 3 fiscal years.
- FY2025 was the lowest level in the 4 fiscal years shown.
What to watch
Whether EBITDA Margin reaches the consensus estimate from 7 analysts of -1148.7% for the fiscal year ending Dec 2026, down from -823.8% in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterMar 2026
- -988.1%+532.6 pp QoQ
- Last fiscal yearDec 2025
- -823.8%-547.5 pp YoY
- LTMMar 2026
- -843.9%-542.0 pp YoY
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA Margin history
Percent of revenue · from the income statement
- Latest · FY2025
- -823.8%
- Year-over-year change
- -547.5pp
| Period | Period end | EBITDA Margin | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | -823.8% | -547.5pp |
| FY2024 | 2024-12-31 | -276.3% | +93.2pp |
| FY2023 | 2023-12-31 | -369.5% | -85.9pp |
| FY2022 | 2022-12-31 | -283.5% | +669.9pp |
| FY2021 | 2021-12-31 | -953.4% | — |
EBITDA Margin vs competitors
How ACRS compares with its peers on the latest reported figures
- ACRS's LTM Mar 2026 EBITDA Margin of -843.9% is the 2nd highest of the 5 companies compared; the peer median is -5450.7%.
- Its year-over-year change of -542.0 pp is the 2nd highest of 4, against a peer median of -3970.2 pp.
- Over three fiscal years its change of -540.2 pp compares with a peer median of +1052.7 pp.
| Company | Period | LTM level | YoY | 3-year change |
|---|---|---|---|---|
| LTM Mar 2026 | 25.2% | +93.4 pp | +1052.7 pp | |
| LTM Mar 2026 | -843.9% | -542.0 pp | -540.2 pp | |
| FY2025 | -4915.2% | — | — | |
ALMSAlumis Inc. Common Stock | LTM Jun 2026 | -5986.3% | -3970.2 pp | — |
| LTM Mar 2026 | -144435.8% | -111246.8 pp | — | |
TRAXFirst Tracks Biotherapeutics Inc | FY2025 | — | — | — |
| FY2025 | — | — | — | |
ODTXOdyssey Therapeutics, Inc. | — | — | — | — |
AGMBAgomAb Therapeutics N.V. American Depositary Shares | FY2024 | — | — | — |
| FY2025 | — | — | — | |
| FY2025 | — | — | — | |
| Peer median (excluding ACRS) | -5450.7% | -3970.2 pp | +1052.7 pp | |
Competitors are the stored peer set for ACRS. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 6.76M | 29.75M | 31.25M | 18.72M | 7.83M |
| Cost of Revenue | 4.71M | 11.96M | 18.08M | 2.79M | 2.09M |
| Gross Profit | 2.05M | 17.79M | 13.17M | 15.93M | 5.74M |
| Gross Margin | 30.3% | 59.8% | 42.1% | 85.1% | 73.3% |
| Research & Development | 43.81M | 77.81M | 98.38M | 33.59M | 52.65M |
| Selling, General & Admin | 23.62M | 25.13M | 31.1M | 22.2M | 21.97M |
| Operating Expenses | 91.77M | 107.65M | 110.53M | 157.86M | 82.11M |
| Depreciation & Amortization | 923K | 797K | 863K | 807K | 454K |
| EBITDA | (64.46M) | (84.36M) | (115.45M) | (51.72M) | (64.47M) |
| EBITDA Margin | -953.4% | -283.5% | -369.5% | -276.3% | -823.8% |
| Operating Income | (89.72M) | (89.85M) | (97.36M) | (141.93M) | (76.38M) |
| Operating Margin | -1327.1% | -302.0% | -311.6% | -758.2% | -975.9% |
| Interest Income | 0 | 0 | 0 | 7.95M | 7.64M |
| Interest Expense | 0 | 0 | 0 | 0 | 0 |
| Other Income / Expenses | (1.14M) | 2.95M | 8.51M | 9.87M | 11.45M |
| Income Before Tax | (90.87M) | (86.91M) | (88.85M) | (132.07M) | (64.92M) |
| Pre-Tax Margin | -1344.0% | -292.1% | -284.3% | -705.5% | -829.6% |
| Income Tax Expense | 0 | 0 | (367K) | 0 | 0 |
| Net Income | (90.87M) | (86.91M) | (88.48M) | (132.07M) | (64.92M) |
| Net Margin | -1344.0% | -292.1% | -283.1% | -705.5% | -829.6% |
| EPS (Basic) | (1.60) | (1.33) | (1.27) | (1.71) | (0.53) |
| EPS (Diluted) | (1.60) | (1.33) | (1.27) | (1.71) | (0.53) |
| Weighted Avg Shares | 56.73M | 65.21M | 69.81M | 77.3M | 122.66M |
| Weighted Avg Shares (Diluted) | 56.73M | 65.21M | 69.81M | 77.3M | 122.66M |
Aclaris Therapeutics, Inc.
NASDAQ:ACRS
Intrinsic Alpha fair value
Locked
Current Price
$3.50
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.